Cytarabine 500mg
| Product Overview | |
| Generic Name | Cytarabine 500mg |
| Brand Name(s) | Cytosar-U |
| Form | Vial, Injectable solution for IV |
| Strength | 500 mg/5 mL |
| Therapeutic Class | Antimetabolite antineoplastic (pyrimidine analog) |
| ATC Code | L01BC01 |
| Manufacturing & Regulatory | |
| Manufacturer | Halsted, Pfizer |
| Country | USA, Canada, India |
| GMP Compliance | WHO-GMP certified |
| DMF/CEP | Type II/III |
| COFEPRIS | 010.000.1775.00 |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 10 units |
| Shelf Life | 24 months |
| Storage | 2–8 °C |
| Incoterms | Ex-Works 30049049 |
| Lead Time | 7 to 10 Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes |
| CTD Summary | CTD proprietary; available under commercial agreement/license |
Description
Cytarabine is an antineoplastic antimetabolite, specifically a pyrimidine nucleoside analogue, used in chemotherapy protocols. Indications for treating acute lymphocytic leukemia, acute granulocytic leukemia, erythroleukemia, and meningeal leukemia.
